tiprankstipranks
Advertisement
Advertisement

Cronos Group Posts Record 2025 Revenue and Eyes European Cannabis Expansion

Story Highlights
  • Cronos Group delivered record 2025 revenue and positive Adjusted EBITDA, supported by strong brand demand and Cronos GrowCo expansion.
  • Backed by a large cash balance, Cronos is pursuing European growth via CanAdelaar and Netherlands adult-use, reinforcing its global cannabis positioning.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cronos Group Posts Record 2025 Revenue and Eyes European Cannabis Expansion

Claim 55% Off TipRanks

Cronos Group ( (TSE:CRON) ) has provided an update.

Cronos Group reported record fourth-quarter and full-year 2025 net revenue, with Q4 sales rising 47% year over year to $44.5 million and full-year revenue up 25% to $146.6 million, driven by strong demand for its leading brands, expanded output from Cronos GrowCo and growing international contributions, particularly in Israel. The company significantly improved profitability metrics, turning Adjusted EBITDA positive for the year, while maintaining an industry-leading cash position of $832 million plus short-term investments, which, along with the pending acquisition of European operator CanAdelaar and its Netherlands adult-use strategy, is expected to strengthen its competitive footing and support sustained growth and long-term value creation.

The most recent analyst rating on (TSE:CRON) stock is a Buy with a C$4.50 price target. To see the full list of analyst forecasts on Cronos Group stock, see the TSE:CRON Stock Forecast page.

Spark’s Take on TSE:CRON Stock

According to Spark, TipRanks’ AI Analyst, TSE:CRON is a Neutral.

Cronos Group’s overall score reflects strong earnings performance and technical momentum, offset by valuation concerns and cash flow challenges. The company’s robust market position in Canada and Israel, coupled with a strong balance sheet, supports future growth, but operational profitability and cash flow issues need resolution.

To see Spark’s full report on TSE:CRON stock, click here.

More about Cronos Group

Cronos Group Inc., listed on Nasdaq and the TSX, operates in the global cannabis industry with a focus on branded cannabis products and international markets. Its portfolio includes the PEACE NATURALS brand, which holds the top market position in Israel’s medical cannabis segment, and it is expanding cultivation capacity through Cronos GrowCo to support growth across key regions.

Average Trading Volume: 242,052

Technical Sentiment Signal: Buy

Current Market Cap: C$1.43B

See more insights into CRON stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1